☆ 4.6 Review

Treating Clostridioides difficile: Could Microbiota-based Live Biotherapeutic Products Provide the Answer?

INFECTION AND DRUG RESISTANCE (2023)

Related references

Note: Only part of the references are listed.

Article Infectious Diseases

Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection

Erik R. Dubberke et al.

Summary: This study reports the safety and efficacy data of using RBX2660 for the treatment of recurrent Clostridioides difficile infection (rCDI). RBX2660, a live biotherapeutic, is effective in reducing CDI recurrence after standard antibiotic treatment. The results showed no significant difference in treatment success between RBX2660 and placebo groups in the intention-to-treat (ITT) and per-protocol (PP) populations, but the PP population had a higher treatment success rate in the RBX2660 group. RBX2660 exhibited a similar safety profile compared to placebo. Although the study did not meet its primary endpoint, the clinical data support further investigation of the single-dose regimen.

INFECTIOUS DISEASES AND THERAPY (2023)

Add to Collection

Editorial Material Infectious Diseases

The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660

Robert Orenstein

Summary: This study describes the long-term efficacy and safety of the microbiota-based live biotherapeutic product RBX2660 in patients with recurrent Clostridioides difficile infection (rCDI). The results show sustained treatment success and restoration of the gut microbiota in patients who received RBX2660. This study provides important insights into the long-term management of CDI and related medical conditions.

INFECTIOUS DISEASES AND THERAPY (2023)

Add to Collection

Article Medicine, General & Internal

VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection A Randomized Clinical Trial

Thomas Louie et al.

Summary: This study aimed to evaluate the efficacy of VE303, a bacterial consortium of eight strains of commensal Clostridia, in preventing recurrent Clostridioides difficile infection (CDI). The results demonstrated that high-dose VE303 was effective in preventing CDI recurrence compared to placebo.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Add to Collection

Article Medicine, General & Internal

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection & nbsp;A Phase 3, Open-Label, Single-Arm Trial

Matthew D. Sims et al.

Summary: A safe and effective treatment for recurrent Clostridioides difficile infection (CDI) is urgently needed. This study evaluated the safety and rate of CDI recurrence after administration of investigational microbiome therapeutic SER-109 through 24 weeks. The results showed that the rate of recurrent CDI was low regardless of the number of prior recurrences, demographics, or diagnostic approach, supporting the beneficial impact of SER-109 for patients with CDI.

JAMA NETWORK OPEN (2023)

Add to Collection

Article Medicine, General & Internal

SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection

Paul Feuerstadt et al.

Summary: SER-109 microbiome therapy is superior to placebo in reducing the risk of recurrent C. difficile infection, and has a similar safety profile as placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Infectious Diseases

Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial

Robert Orenstein et al.

Summary: In this Phase 2 trial, RBX2660 was found to be safe and effective in reducing the recurrence of rCDI compared to a historical control group. Microbiome changes in participants treated with RBX2660 were consistent with protective changes against C. difficile recurrence.

BMC INFECTIOUS DISEASES (2022)

Add to Collection

Article Microbiology

Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers

Melissa Dsouza et al.

Summary: Manipulating the gut microbiota through fecal microbiota transplantation shows promise in treating certain diseases. Live biotherapeutic products consisting of defined bacterial strains have potential as an alternative therapeutic option.

CELL HOST & MICROBE (2022)

Add to Collection

Article Immunology

730. A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ridinilazole Compared with Vancomycin for the Treatment of Clostridioides difficile Infection

Pablo C Okhuysen et al.

Open Forum Infectious Diseases (2022)

Add to Collection

Article Microbiology

Gut metabolites predict Clostridioides difficile recurrence

Jennifer J. Dawkins et al.

Summary: This study conducted a longitudinal analysis of the gut microbiome and metabolome changes in patients with primary Clostridioides difficile infection (CDI). The results showed that metabolomic data can accurately predict the recurrence of CDI, providing important insights for the development of diagnostic tests and treatments.

MICROBIOME (2022)

Add to Collection

Article Pharmacology & Pharmacy

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection

Sahil Khanna et al.

Summary: RBX2660 is a safe and effective treatment option for reducing recurrent C. difficile infection following standard-of-care antibiotics, with a sustained response lasting up to 6 months.

DRUGS (2022)

Add to Collection

Review Infectious Diseases

SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)

Sahil Khanna et al.

Summary: Clostridioides difficile infection (CDI) is a urgent health threat with a high recurrence risk. Current CDI treatment strategies do not address microbiome disruption, but fecal microbiota transplantation (FMT) reduces the risk of recurrence. SER-109, an oral microbiome therapeutic, reduces CDI recurrence and has a favorable safety profile. This article discusses the role of the microbiome in CDI pathogenesis and the clinical development of SER-109.

ANTIBIOTICS-BASEL (2022)

Add to Collection

Review Gastroenterology & Hepatology

The role of the gut microbiome in colonization resistance and recurrent Clostridioides difficile infection

Anna Maria Seekatz et al.

Summary: The composition of the human gut microbiota is important for overall health, and disruptions in this microbiome can lead to various diseases. In the case of Clostridioides difficile infection, standard treatments and monoclonal antibodies do not address the underlying dysbiosis. Fecal microbiota transplantation (FMT) is an effective strategy in preventing recurrent infections, but there are challenges in screening and standardizing the acquisition and processing of donor stool. Newer biotherapeutic formulations are being developed to improve gut microbiome restoration and prevent CDI recurrence.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2022)

Add to Collection

Article Immunology

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial

Barbara H. McGovern et al.

Summary: The study results suggest that SER-109 has the potential to prevent rCDI, especially for patients over 65 years old. Early engraftment of SER-109 is associated with non-recurrence and increased concentrations of secondary bile acids.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients' Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections

Sahil Khanna et al.

Summary: RBX7455, an orally administered investigational live biotherapeutic, was found to be safe and effective in preventing rCDI recurrence. Participants who received RBX7455 showed no recurrence at 8-week endpoint and up to 6 months later. The microbiome composition of participants shifted towards that of RBX7455 after treatment.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Gastroenterology & Hepatology

S131 CP101, an Investigational Orally Administered Microbiome Therapeutic, Increases Intestinal Microbiome Diversity and Prevents Recurrent C. difficile Infection: Results From a Randomized, Placebo-Controlled Trial

Sahil Khanna et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2021)

Add to Collection

Review Infectious Diseases

Predictors of failure after fecal microbiota transplantation for recurrent Clostridioides difficile infection: a systematic review and meta-analysis

Raseen Tariq et al.

Summary: Fecal microbiota transplantation (FMT) is an effective therapy for CDI, but has a failure rate of around 15%. Factors such as use of non-CDI antibiotics, presence of inflammatory bowel disease, poor bowel preparation, CDI-related hospitalization before FMT, inpatient FMT, and severe CDI are associated with increased risk of FMT failure. Modifiable factors like antibiotic use post-FMT and good bowel preparation can lower the risk of failure. Patients with non-modifiable risk factors should be more vigilant for recurrent symptoms after FMT.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2021)

Add to Collection

Review Medicine, General & Internal

Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day!

S. Khanna

Summary: Clostridioides difficile infection (CDI) is a common healthcare-associated infection, with management difficulties and high rates of recurrence. Microbiota restoration therapies, such as faecal microbiota transplantation, are the cornerstone for preventing recurrent CDI, with success rates over 90%. Developments in standardized microbiota restoration therapies, such as capsule-based and enema-based therapies, are emerging to improve management of CDI.

JOURNAL OF INTERNAL MEDICINE (2021)

Add to Collection

Article Microbiology

The Bacterial Gut Microbiota of Adult Patients Infected, Colonized or Noncolonized by Clostridioides difficile

Monique J. T. Crobach et al.

MICROORGANISMS (2020)

Add to Collection

Article Medicine, Research & Experimental

Metabolomic networks connect host-microbiome processes to human Clostridioides difficile infections

John Robinson et al.

JOURNAL OF CLINICAL INVESTIGATION (2019)

Add to Collection

Article Immunology

1953. VE303, a Rationally Designed Bacterial Consortium for Prevention of Recurrent Clostridioides difficile (C. Difficile) infection (rCDI), Stably Restores the Gut Microbiota After Vancomycin (vanco)-Induced Dysbiosis in Adult Healthy Volunteers (HV)

Dmitri Bobilev et al.

Open Forum Infectious Diseases (2019)

Add to Collection

Article Immunology

Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)

L. Clifford McDonald et al.

CLINICAL INFECTIOUS DISEASES (2018)

Add to Collection

Article Multidisciplinary Sciences

Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin

Cheleste M. Thorpe et al.

PLOS ONE (2018)

Add to Collection

Article Microbiology

Recovery of gut microbiota of healthy adults following antibiotic exposure

Albert Palleja et al.

NATURE MICROBIOLOGY (2018)

Add to Collection

Article Multidisciplinary Sciences

The evolution of the host microbiome as an ecosystem on a leash

Kevin R. Foster et al.

NATURE (2017)

Add to Collection

Review Gastroenterology & Hepatology

Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection

M. N. Quraishi et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)

Add to Collection

Article Immunology

Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study

Robert Orenstein et al.

CLINICAL INFECTIOUS DISEASES (2016)

Add to Collection

Article Immunology

A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection

Sahil Khanna et al.

JOURNAL OF INFECTIOUS DISEASES (2016)

Add to Collection

Article Medicine, General & Internal

Burden of Clostridium difficile Infection in the United States

Fernanda C. Lessa et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Editorial Material Microbiology

The vocabulary of microbiome research: a proposal

Julian R. Marchesi et al.

MICROBIOME (2015)

Add to Collection

Article Immunology

The Roles of Clostridium difficile and Norovirus Among Gastroenteritis-Associated Deaths in the United States, 1999-2007

Aron J. Hall et al.

CLINICAL INFECTIOUS DISEASES (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.